http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7691817-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4e40437dddb4da1e093f63a0a7c1f316 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fc37a2e81be7220b8efdb88f46d09527 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-046 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M31-00 |
| filingDate | 2004-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2010-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b68ff0e73218e04b35469fceb512af8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3db772d7650b0d9c0954576ba484a3d |
| publicationDate | 2010-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-7691817-B2 |
| titleOfInvention | System and method for inhibiting cellular proliferation with tachykinins |
| abstract | Systems and methods are described providing therapeutic preparations of tachykinins, and more specifically sialokinins, for treating various types of abnormal cellular proliferation conditions in regions of tissue associated with the body of a patient. The sialokinins may be isolated and purified from natural or bioengineered sources, or may be synthesized, and may be combined into, with, or on an implant for local elution or otherwise as a powder mixed in a carrier vehicle for injection delivery. Tumors, warts, and restenosis are abnormal cellular proliferation conditions treated by therapeutic doses of sialokinin. Size of the tissue structure to be treated is used to determine the therapeutic dose of sialokinin. The sialokinins are either locally or systemically delivered at therapeutic doses for the desired effect. Implants such as stents are coated with sialokinins for local elution at the site of injury or tissue otherwise vulnerable to harmful conditions treated by the sialokinin. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8357653-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011009334-A1 |
| priorityDate | 2002-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 625.